Apnimed president reports option grants, share swap
Apnimed, Inc. President Dennis Patrick Molnar reported a series of internal equity adjustments and option grants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Apnimed, Inc. President Dennis Patrick Molnar reported a series of internal equity adjustments and option grants. On 2026-08-03, each share of Class A Common Stock was reclassified into one share of Common Stock under Rule 16b-7 and Rule 16b-3, resulting in paired dispositions and acquisitions of both common shares and multiple stock option awards at exercise prices ranging from $1.00 to $16.00 per share. A separate stock option for 55,596 shares at $16.00 per share was granted on 2026-07-30, vesting in substantially equal monthly installments over 24 months after July 30, 2026.
Insider Trade Summary
19 transactions reported
Mixed
19 txns
Insider
Molnar Dennis Patrick
Role
President
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F1, F2 | 330,210 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 330,210 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F2 | 42,240 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 42,240 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F2 | 148,788 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 148,788 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F2 | 37,064 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F2 | 37,064 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F3 | 28,539 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F3 | 28,539 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F4 | 37,064 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) Stock Option (Right to Buy) F1, F4 | 37,064 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F5 | 12,231 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F5 | 12,231 | $0.00 | $0.00 |
| Disposition | Stock Option (Right to Buy) F1, F6 | 55,596 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F1, F6 | 55,596 | $0.00 | $0.00 |
| Disposition | Class A Common Stock F1 | 58,014 | -- | -- |
| Grant/Award | Common Stock F1 | 58,014 | -- | -- |
| Grant/Award | Stock Option (Right to Buy) F6 | 55,596 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 654,668 contracts (Direct);
Stock Option (Right to Buy) Stock Option (Right to Buy) — 37,064 contracts (Direct);
Class A Common Stock — 0 shares (Direct);
Common Stock — 58,014 shares (Direct)
Footnotes (6)
- F1. Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
- F2. 100% of the shares subject to such option are fully vested.
- F3. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after December 22, 2022, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F4. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after December 21, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F5. 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 17, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
- F6. The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 24 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Option block at $1.00: 330,210 shares at $1.0000 per share
Additional $1.00 option block: 42,240 shares at $1.0000 per share
Option block at $1.06: 148,788 shares at $1.0600 per share
+5 more
8 metrics
Option block at $1.00
330,210 shares at $1.0000 per share
Stock Option (Right to Buy) expiring 2029-01-24; reclassified from Class A to Common Stock
Additional $1.00 option block
42,240 shares at $1.0000 per share
Stock Option (Right to Buy) expiring 2030-01-29; reclassified from Class A to Common Stock
Option block at $1.06
148,788 shares at $1.0600 per share
Stock Option (Right to Buy) expiring 2030-03-31; reclassified from Class A to Common Stock
Option block at $2.74
37,064 shares at $2.7400 per share
Stock Option (Right to Buy) expiring 2032-06-14; reclassified from Class A to Common Stock
Option block at $4.00
28,539 shares at $4.0000 per share
Stock Option (Right to Buy) expiring 2032-12-22; time-based vesting from December 22, 2022
Option block at $4.87
37,064 shares at $4.8700 per share
Stock Option (Right to Buy) expiring 2033-12-21; time-based vesting from December 21, 2023
Option block at $8.88
12,231 shares at $8.8800 per share
Stock Option (Right to Buy) expiring 2035-09-19; vesting from September 17, 2025
Option grant at $16.00
55,596 shares at $16.0000 per share
Stock Option (Right to Buy) expiring 2036-07-29; monthly vesting over 24 months after July 30, 2026
Key Terms
Rule 16b-7, Rule 16b-3, Class A Common Stock, Common Stock, +2 more
6 terms
Rule 16b-7 regulatory
"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3"
A U.S. Securities and Exchange Commission safe-harbor rule that shields corporate insiders (officers, directors and large shareholders) from automatic short-swing profit claims when they buy or sell their company’s stock under a pre-approved, written plan that follows specific timing and nondiscretionary rules. For investors, the rule matters because it distinguishes routine, formula-driven insider transactions from opportunistic trades that could trigger automatic profit recoveries—think of it as an approved autopilot for insider trading that reduces legal uncertainty when the plan’s conditions are met.
Rule 16b-3 regulatory
"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Class A Common Stock financial
"each share of Class A Common Stock was reclassified into one share"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
Common Stock financial
"reclassified into one share of Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
stock option financial
"The shares subject to such option vest and become exercisable"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Apnimed (APMD) President Dennis Patrick Molnar report on August 3, 2026?
Dennis Patrick Molnar reported paired dispositions and acquisitions of Class A and Common Stock and related options on 2026-08-03. These reflect a reclassification of Class A Common Stock into Common Stock and corresponding adjustments to multiple stock option grants, not open-market trades.
How many Apnimed (APMD) options at a $1.00 exercise price were affected in Molnar’s filing?
The filing shows paired transactions involving 330,210 stock options at a $1.00 exercise price and 42,240 options at the same price. Each block was first shown as a disposition of Class A stock options and a matching acquisition of Common Stock options under the reclassification.
Are any of Dennis Molnar’s Apnimed (APMD) stock options fully vested according to the Form 4?
Yes. A footnote indicates that for certain options, 100% of the shares subject to those options are fully vested. Other option blocks have time-based vesting schedules tied to Molnar’s ongoing continuous service with the company.
Did Dennis Molnar’s Apnimed (APMD) Form 4 report open-market purchases or sales?
No open-market purchases or sales are shown. The transactions are coded primarily as acquisitions (A) and dispositions to the issuer (D) related to an internal share reclassification and option grants, rather than public market trading activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
